JP2009544758A5 - - Google Patents

Download PDF

Info

Publication number
JP2009544758A5
JP2009544758A5 JP2009522956A JP2009522956A JP2009544758A5 JP 2009544758 A5 JP2009544758 A5 JP 2009544758A5 JP 2009522956 A JP2009522956 A JP 2009522956A JP 2009522956 A JP2009522956 A JP 2009522956A JP 2009544758 A5 JP2009544758 A5 JP 2009544758A5
Authority
JP
Japan
Prior art keywords
compound
formula
disease
salt
temperature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009522956A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009544758A (ja
Filing date
Publication date
Priority claimed from US11/782,704 external-priority patent/US7671062B2/en
Application filed filed Critical
Publication of JP2009544758A publication Critical patent/JP2009544758A/ja
Publication of JP2009544758A5 publication Critical patent/JP2009544758A5/ja
Withdrawn legal-status Critical Current

Links

JP2009522956A 2006-07-28 2007-07-26 ケモカイン受容体活性のモジュレーター、結晶形および方法 Withdrawn JP2009544758A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US83423506P 2006-07-28 2006-07-28
US89602607P 2007-03-21 2007-03-21
US11/782,704 US7671062B2 (en) 2006-07-28 2007-07-25 Modulators of chemokine receptor activity, crystalline forms and process
PCT/US2007/074438 WO2008014381A2 (en) 2006-07-28 2007-07-26 Modulators of chemokine receptor activity, crystalline forms and process

Publications (2)

Publication Number Publication Date
JP2009544758A JP2009544758A (ja) 2009-12-17
JP2009544758A5 true JP2009544758A5 (enExample) 2010-08-12

Family

ID=38823540

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009522956A Withdrawn JP2009544758A (ja) 2006-07-28 2007-07-26 ケモカイン受容体活性のモジュレーター、結晶形および方法

Country Status (29)

Country Link
US (1) US7671062B2 (enExample)
EP (2) EP2049477B1 (enExample)
JP (1) JP2009544758A (enExample)
KR (1) KR20090035036A (enExample)
CN (1) CN101511822A (enExample)
AR (1) AR062114A1 (enExample)
AT (1) ATE471928T1 (enExample)
AU (1) AU2007279256A1 (enExample)
BR (1) BRPI0715066A2 (enExample)
CA (1) CA2659259A1 (enExample)
CL (3) CL2007002196A1 (enExample)
CO (1) CO6190527A2 (enExample)
CY (1) CY1110785T1 (enExample)
DE (1) DE602007007335D1 (enExample)
DK (1) DK2049477T3 (enExample)
EA (1) EA014960B1 (enExample)
ES (1) ES2346591T3 (enExample)
HR (1) HRP20100371T1 (enExample)
IL (1) IL196518A0 (enExample)
MX (1) MX2009000803A (enExample)
NO (1) NO20090256L (enExample)
NZ (1) NZ574656A (enExample)
PE (1) PE20080838A1 (enExample)
PL (1) PL2049477T3 (enExample)
PT (1) PT2049477E (enExample)
SG (1) SG158925A1 (enExample)
SI (1) SI2049477T1 (enExample)
TW (1) TW200823203A (enExample)
WO (1) WO2008014381A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7687508B2 (en) * 2006-07-28 2010-03-30 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
US8383812B2 (en) 2009-10-13 2013-02-26 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
SI3297438T1 (sl) * 2015-05-21 2022-03-31 Chemocentryx, Inc. CCR2 modulatorji
PL3655395T3 (pl) * 2017-07-20 2022-03-07 Bristol-Myers Squibb Company Proces otrzymywania n-((1r,2s,sr)-5-(tert-butyloamino)-2-((s)-3-(7-tert-butylopirazolo[1,5-a][1,3,5]triazyn-4-yloamino)-2-oksopirolidyn-1-ylo)cykloheksylo)acetamidu
EP3687525B1 (en) 2017-09-25 2025-10-29 ChemoCentryx, Inc. Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor
ES2991280T3 (es) 2018-01-08 2024-12-03 Chemocentryx Inc Antagonistas de CCR2 para el tratamiento del linfoma cutáneo de linfocitos T
US20190269664A1 (en) 2018-01-08 2019-09-05 Chemocentryx, Inc. Methods of treating solid tumors with ccr2 antagonists
CN115494184B (zh) * 2022-05-09 2023-07-28 浙江海正药业股份有限公司 一种同时检测药物中异丙苯磺酸甲酯、异丙苯磺酸乙酯的方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6383082A (ja) 1986-09-26 1988-04-13 Takeda Chem Ind Ltd テトラヒドロフランカルボン酸誘導体の製造法
CA2084800A1 (en) 1991-12-16 1993-06-17 Joseph P. Vacca Hiv protease inhibitors with an internal lactam ring
GB9515411D0 (en) 1995-07-27 1995-09-27 Pharmacia Spa N-(4-substituted-benzyl)-2-aminolactam derivatives
US5827875A (en) 1996-05-10 1998-10-27 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
UA51716C2 (uk) 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
US6054579A (en) 1997-06-26 2000-04-25 Leukosite, Inc. Synthesis of substituted lactams
GB9716656D0 (en) 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
HUP0101810A3 (en) 1998-01-27 2002-05-28 Aventis Pharm Prod Inc Substituted oxoazaheterocyclyl factor xa inhibitors and pharmaceutical compositions containing them
JP2002501944A (ja) 1998-01-29 2002-01-22 アヴェンティス ファーマシューティカルズ プロダクツ インコーポレイテッド N−[(脂肪族又は芳香族)カルボニル]−2−アミノアセトアミド化合物及び環化化合物の製造方法
US6492553B1 (en) 1998-01-29 2002-12-10 Aventis Pharamaceuticals Inc. Methods for preparing N-[(aliphatic or aromatic)carbonyl)]-2-aminoaetamide compounds and for cyclizing such compounds
GB9803228D0 (en) 1998-02-17 1998-04-08 Zeneca Ltd Chemical compounds
US6541208B1 (en) 1998-03-17 2003-04-01 University Of Maryland Biotechnology Institute Diagnostic method for distinguishing HIV-associated dementia from other forms of dementia
WO2001017992A1 (en) 1999-09-09 2001-03-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6620823B2 (en) 2000-07-11 2003-09-16 Bristol-Myers Squibb Pharme Company Lactam metalloprotease inhibitors
CA2432908A1 (en) 2000-12-20 2002-06-27 Bristol-Myers Squibb Pharma Company Diamines as modulators of chemokine receptor activity
HUP0303652A2 (hu) 2000-12-20 2004-03-01 Bristol-Myers Squibb Company Ciklikus származékok, mint kemokin receptor aktivitás modulátorai és ezeket tartalmazó gyógyszerkészítmények
DE60209471D1 (de) 2001-03-29 2006-04-27 Topo Target As Copenhagen Koeb Succinimid- und maleimidderivate und ihre verwendung als katalytische inhibitoren der topoisomerase ii
GB0114867D0 (en) 2001-06-18 2001-08-08 Merck Sharp & Dohme Therapeutic agents
DE10135043A1 (de) 2001-07-11 2003-01-30 Bayer Cropscience Gmbh Substituierte 3-Heteroaryl(amino- oder oxy)-pyrrolidin-2-one, Verfahren zu deren Herstellung und Verwendung als Herbizide oder als Pflanzenwachstumsregulatoren
AU2003218028A1 (en) 2002-03-08 2003-09-22 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
TW200307667A (en) 2002-05-06 2003-12-16 Bristol Myers Squibb Co Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
WO2004022536A1 (en) 2002-09-04 2004-03-18 Glenmark Pharmaceuticals Limited New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
WO2004071449A2 (en) 2003-02-12 2004-08-26 Bristol-Myers Squibb Company Lactams as modulators of chemokine receptor activity
TW200508224A (en) 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
US7291615B2 (en) 2003-05-01 2007-11-06 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
US7230133B2 (en) 2003-05-01 2007-06-12 Bristol-Myers Squibb Company Malonamides and malonamide derivatives as modulators of chemokine receptor activity
US20060205761A1 (en) 2003-06-06 2006-09-14 Catherine Abbadie Ccr-2 antagonists for treatment of neuropathic pain
US7378409B2 (en) 2003-08-21 2008-05-27 Bristol-Myers Squibb Company Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
US7317019B2 (en) 2003-08-21 2008-01-08 Bristol Myers Squibb Co. N-alkylated diaminopropane derivatives as modulators of chemokine receptor activity
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
US20050043392A1 (en) 2003-08-21 2005-02-24 Carter Percy H. Lactams of alkylated acyclic diamine derivatives as modulators of chemokine receptor activity
US7863317B2 (en) 2003-08-21 2011-01-04 Bristol-Myers Squibb Company Lactams of alkylated acyclic diamine derivatives as modulators of chemokine receptor activity
MX2007001204A (es) 2004-07-30 2007-03-23 Pfizer Prod Inc Procedimientos para tratar las enfermedades o trastornos mediados por ccr2.
WO2006036527A1 (en) 2004-09-28 2006-04-06 Janssen Pharmaceutica, N.V. Substituted dipiperdine ccr2 antagonists

Similar Documents

Publication Publication Date Title
JP2009544758A5 (enExample)
JP6966590B2 (ja) オメカムチブメカルビルの塩及び塩を調製するプロセス
NL1026438C2 (nl) Nieuwe verbindingen.
JP2009544756A5 (enExample)
JP5273587B2 (ja) キナゾリンジオン骨格を有するフェニルアラニン誘導体の製造方法及び製造中間体
TW201720825A (zh) 二氫吡啶並環化合物的晶型、製備方法和中間體
JP2005503386A5 (enExample)
JP2013532164A (ja) トロンビン特異的インヒビターを調製する方法
AU2007275415A2 (en) Proline urea CCR1 antagonists for the treatment of autoimmune diseases or inflammation
JP2009508949A5 (enExample)
JPWO2014017515A1 (ja) 4−[5−(ピリジン−4−イル)−1h−1,2,4−トリアゾール−3−イル]ピリジン−2−カルボニトリルの結晶多形およびその製造方法
CA2660320A1 (en) Morpholinyl and pyrrolidinyl analogs
HRP20140072T1 (hr) N-((1r,2s,5r)-5-(terc-butilamino)-2-((s)-3-(7-terc-butilpirazolo[1,5-a][1,3,5]triazin-4-ilamino)-2-oksopirolidin-1-il)cikliheksil)acetamid, dvostruki modulator aktivnosti receptora za hemokin, kristalni oblici i postupci
HRP20100371T1 (hr) Modulatori aktivnosti kemokinskih receptora, kristalni oblici i postupci
JP2024503855A (ja) アミノピリミジン系fak阻害剤化合物を合成する方法
AU2012229859B2 (en) Nitrogen-containing saturated heterocyclic compound
HRP20110465T1 (hr) Modulatori aktivnosti receptora kemokina, kristalni oblici i postupak
CN107810189B (zh) 用于制备氮芥衍生物的方法
CN116947763A (zh) 2-巯基-5-氰基-6-芳基嘧啶杂环类化合物、制备方法和应用
CN104610195A (zh) 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
WO2018233727A1 (zh) 一种吲哚类化合物及其应用,一种药物组合物及其应用
KR20100017565A (ko) (r)-2-메틸피롤리딘 및 (s)-2-메틸피롤리딘 및 이의 타르트레이트 염의 제조 방법
JP2018526372A (ja) Rorガンマ調節剤としての新規の炭素環化合物
CN106316876B (zh) β-羰基丙烯酰胺类化合物、其制备方法及应用
JP2008540538A5 (enExample)